IntelGenx announces multiple commercialization agreements with Chemo Group in 2017

05-Jan-2017 - Last updated on 05-Jan-2017 at 15:36 GMT

Founded in 1978, Chemo Group markets more than 300 products.(Image: Chemo Group)

IntelGenx Corp has granted Chemo Group an exclusive worldwide license to commercialize several products – moving the company into the novel drug delivery market.

“Chemo has signed four products with us in 2017,” Edward Miller, Director, IR and Corporate Communications at IntelGenx, told Outsourcing-Pharma.com. “We will work with Chemo to develop these products to commercialization.”

According to the oral drug delivery company company, the combined total market of the four products is more than $7bn. The partnership could also present future opportunities for further product agreements.

Per the agreement, IntelGenx is entitled to an upfront payment, development costs of the product and future milestone payments. A total value of which is in the seven digits, according to IntelGenx.

The companies will share the commercialization profits.

IntelGenx also recently built a new oral film development and manufacturing facility in Montreal, Canada. Construction was completed in Q1 2016 and the facility is expected to be fully operational by Q1 2017. The 17,000 sq ft facility features high capacity manufacturing and packaging equipment.